Filip Komar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Filip Komar has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Marcysiak
Medical University of Lublin, Aleje Racławickie 1, 20-059 Lublin, Poland
1 shared publication - Artur Marcysiak
Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach, ul. Poniatowskiego 26, 08-110 Siedlce, Poland
1 shared publication - Iga Poprawa
Medical University of Warsaw, Warsaw, Poland
1 shared publication - Małgorzata Landowska
Department of Internal Medicine, Endocrinology and Diabetology, National Medical Institute of the Ministry of the Interior and Administration in Warsaw, 02-507 Warsaw, Poland
1 shared publication - Michał Stermach
Medical University of Warsaw, Warsaw, Poland
1 shared publication - Nina Kubikowska
Medical University of Warsaw, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
TARGETED THERAPIES AND IMMUNOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER – CURRENT STANDARDS AND NEW DIRECTIONS
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, but advances in targeted therapies and immunotherapy have radically changed the prognosis of advanced disease. The introduction of tyrosine kinase inhibitors directed against alterations in EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, NTRK, HER2 and other genes has led to a shift away from uniform chemotherapy toward treatment based on precise molecular characterization of the tumor. In parallel, immune checkpoint–blocking antibodies, primarily targeting PD-1/PD-L1 and CTLA-4, have become the standard of care in first and subsequent lines of treatment for patients without oncogenic drivers, used both as monotherapy and in combination with chemotherapy and anti-angiogenic agents. Despite substantial survival gains, most patients develop primary or acquired resistance to targeted therapy and immunotherapy, which represents a major clinical challenge. This article reviews current standards of care in advanced NSCLC, emphasizing the role of molecular testing and PD-L1 assessment in therapy selection, the place of combination regimens including immune checkpoint inhibitors, and emerging strategies to overcome resistance, such as next-generation inhibitors, bispecific antibodies, antibody–drug conjugates, neoantigen vaccines and cellular therapies. Particular attention is given to future perspectives for further personalization of treatment, the role of predictive biomarkers (including PD-L1, TMB and ctDNA), and ongoing and planned studies of combination approaches that may further improve outcomes for patients with advanced NSCLC.
- 20 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessTARGETED THERAPIES AND IMMUNOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER – CURRENT STANDARDS AND NEW DIRECTIONS
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, but advances in targeted therapies and immunotherapy have radically changed the prognosis of advanced disease. The introduction of tyrosine kinase inhibitors directed against alterations in EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, NTRK, HER2 and other genes has led to a shift away from uniform chemotherapy toward treatment based on precise molecular characterization of the tumor. In parallel, immune checkpoint–blocking antibodies, primarily targeting PD-1/PD-L1 and CTLA-4, have become the standard of care in first and subsequent lines of treatment for patients without oncogenic drivers, used both as monotherapy and in combination with chemotherapy and anti-angiogenic agents. Despite substantial survival gains, most patients develop primary or acquired resistance to targeted therapy and immunotherapy, which represents a major clinical challenge. This article reviews current standards of care in advanced NSCLC, emphasizing the role of molecular testing and PD-L1 assessment in therapy selection, the place of combination regimens including immune checkpoint inhibitors, and emerging strategies to overcome resistance, such as next-generation inhibitors, bispecific antibodies, antibody–drug conjugates, neoantigen vaccines and cellular therapies. Particular attention is given to future perspectives for further personalization of treatment, the role of predictive biomarkers (including PD-L1, TMB and ctDNA), and ongoing and planned studies of combination approaches that may further improve outcomes for patients with advanced NSCLC.